Cysteine-Rich Domain of Human ADAM 12 (Meltrin α) Supports Tumor Cell Adhesion

Kousuke Iba, Reidar Albrechtsen, Brent J. Gilpin, Frosty Loechel, and Ulla M. Wewer

From the Institute of Molecular Pathology, University of Copenhagen, Copenhagen, Denmark

The ADAMs (A disintegrin and metalloprotease) comprise a family of membrane-anchored cell surface proteins with a putative role in cell-cell and/or cell-matrix interactions. By immunostaining, ADAM 12 (meltrin α) was up-regulated in several human carcinomas and could be detected along the tumor cell membranes. Because of this intriguing staining pattern, we investigated whether human ADAM 12 supports tumor cell adhesion. Using an in vitro assay using recombinant polypeptides expressed in Escherichia coli, we examined the ability of individual domains of human ADAM 12 and ADAM 15 to support tumor cell adhesion. We found that the disintegrin-like domain of human ADAM 15 supported adhesion of αvβ3-expressing A375 melanoma cells. In the case of human ADAM 12, however, recombinant polypeptides of the cysteine-rich domain but not the disintegrin-like domain supported cell adhesion of a panel of carcinoma cell lines. On attachment to recombinant polypeptides from the cysteine-rich domain of human ADAM 12, most tumor cell lines, such as MDA-MB-231 breast carcinoma cells, were rounded and associated with numerous actin-containing filopodia and used a cell surface heparan sulfate proteoglycan to attach. Finally, we demonstrated that authentic full-length human ADAM 12 could bind to heparin-Sepharose. Together these results suggest a novel role of the cysteine-rich domain of ADAM 12 — that of supporting tumor cell adhesion. (Am J Pathol 1999, 154:1489–1501)

Cell-cell and cell-matrix interactions are known to critically determine cell adhesion, cell migration, cell survival, and proliferation, processes that play key roles in cancer invasion and metastasis. Several major classes of membrane-bound cell adhesion molecules have been described: immunoglobulin superfamily members, cadherins, integrins, selectins, and cell-surface proteoglycans. Recently the ADAMs (A disintegrin and metalloprotease), a large family of type-I membrane-bound cell surface proteins, have been added to the list. The ADAMs have been referred to by other names, including cellular disintegrins and MDCs (for metalloprotease/disintegrin/cysteine).

The ADAMs have a unique domain organization, including metalloprotease, disintegrin-like, cysteine-rich, transmembrane, and cytoplasmic domains. The closest homologues of ADAMs are the highly toxic snake venom metalloproteases (SVMPs). Both SVMPs and ADAMs are members of the repolysin/adamalysin subfamily of zinc-dependent metalloproteases. The SVMPs are known to degrade basement membrane components, including type-IV collagen, laminin, and fibronectin, thereby leading to hemorrhage in the tissue. Some SVMP disintegrin domains contain an arginine-glycine-aspartic acid (RGD) integrin ligand sequence in a β-loop structure that binds with high affinity to αvβ3 and αIIbβ3 integrins and can inhibit the function of platelet integrin αIIbβ3. Interestingly, such disintegrins are 3000 to 30,000 times more active than small RGD-containing peptides in inhibiting adenosine diphosphate (ADP)-induced platelet aggregation. It has been suggested that SVMP disintegrin domains can disrupt other types of integrin-mediated cell-cell and cell-matrix interactions; in fact there is evidence that eristostatin can reduce the number of lung metastases following tail vein injection of B16F10 melanoma cells and in the liver following injection via mesenteric veins.

Their intriguing composition and homology to the SVMPs suggest that the ADAMs could be active in cell adhesion and proteolysis in a wide variety of biological processes. Although at least 23 ADAMs have been cloned so far, the tissue distribution pattern and function of some of these proteins are only beginning to be unraveled. Several ADAMs such as fertilin α/β and cyritestin have been implicated in fertilization and/or spermatogenesis, in fact targeted disruption of the fertilin β in the mouse results in impaired fertilization. There is ample evidence that the ADAMs on the sperm bind to an integrin on the egg plasma membrane, leading to cell fusion. Interest in the ADAM proteins mounted when it was shown that ADAM 10 and 17 (TACE) can process

Supported by grants from the Danish Cancer Society, the Danish Medical Research Council, and by the VELUX, Novo-Nordisk, Haensch, Munksgaard, Thaysen, Beckett, Hartmann, and Meyer Foundations.

Accepted for publication February 5, 1999.

Address reprint requests to Dr. Ulla M Wewer, Institute of Molecular Pathology, University of Copenhagen, Frederik VI’s vej 11, 2100 Copenhagen, Denmark. E-mail: molera@inet.uni-c.dk.
tumor necrosis factor-α24–27 and that the Drosophila ADAM KUZ is involved in the processing of Notch.28 Of additional interest is the proposed role for ADAMs in proteolyzing insulin-like growth factor binding proteins.29 These results point to an important role of the ADAM proteins in ectodomain shedding.8

We have recently cloned and begun to characterize human ADAM 12.30,31 We found that in addition to the expected membrane-anchored form, designated ADAM 12-L, an alternatively spliced, secreted form exists, designated ADAM 12-S. Furthermore, we demonstrated that a minigene of adadam 12-S, encoding the disintegrin-like, the cysteine-rich, and the unique carboxy-terminus, provoked myogenesis in a nude mouse-model system. Our results and those obtained by Yagami-Hiromasa et al32 using the mouse C2C12 myoblast model system point to a role of ADAM 12 in cell-cell interactions and differentiation.

In the present study we show by immunostaining and reverse transcriptase-polymerase chain reaction (RT-PCR) that ADAM 12 is up-regulated in human carcinoma specimens and that ADAM 12 appears to be located at the tumor cell surfaces. This led us to hypothesize that ADAM 12 is involved in cellular interactions in cancer, and we explored the interaction between ADAM 12 and the cell surface of several cultured tumor cell lines. We found that a recombinant polypeptide from the cysteine-rich domain of human ADAM 12 expressed in Escherichia coli supports cell adhesion by engaging a cell surface heparan sulfate proteoglycan receptor.

Materials and Methods

Tissue Samples and Cell Lines

Tissue specimens from 37 histologically confirmed cases of human carcinomas comprised 15 infiltrating ductal breast carcinoma, 14 adenocarcinoma of the colon and rectum, four squamous cell carcinoma of the lung, and four adenocarcinoma of the stomach. Adjacent nontumor tissue, including 10 samples of normal breast tissue of which nine corresponded to samples from patients with carcinoma, were also investigated. Tissue samples were either snap-frozen in liquid nitrogen and stored at −80°C or were fixed in 96% ethanol/glacial acetic acid (99:1 v/v) overnight, embedded in paraffin, and stored at 4°C.53 Tissue samples were obtained from the Department of Surgical Pathology, University of Copenhagen and Nykøbing Falster Hospital, Denmark.

The following 11 human tumor cell lines were used: MDA-MB-231 breast carcinoma (HTB 26), MDA-MB-435 breast carcinoma,34 MDA-MB-468 breast carcinoma (HTB 132), MCF-7 breast carcinoma (HTB 22), RKO colon carcinoma,35 Clone A colon carcinoma,36 A431 squamous cell carcinoma (CRL 1555), A375 melanoma (CRL 1619), SK-MEL-28 melanoma (ATCC 72), HT1080 fibrosarcoma (CCL 121), and A204 rhabdomyosarcoma (HTB 82). The MDA-MB-435, RKO, and Clone A cells were purchased from Dr. A. M. Mercurio, Harvard Medical School (Boston, MA) and the remainder from the American Type Culture Collection (Rockville, MD). The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with Glutamax I and 4500 mg/ml glucose, 50 U/ml penicillin, 50 μg/ml streptomycin, and 10% fetal bovine serum (Gibco-BRL, Grand Island, NY) at 37°C in 5% CO2 in air and serially passaged using trypsin/EDTA.

Antibodies

A number of monoclonal and polyclonal antibodies to human ADAM 12 were used.30 Rabbit polyclonal antisera included rb104, rb950, R20, R21, R23, M11. Rat monoclonal antibodies included the 14E3 hybridoma and a newly developed hybridoma, 16E8. The antibodies were raised against recombinant cysteine-rich domain of human ADAM 12 (aa 564–708; p1053, see below) and characterized as described.30 The antibodies react in immunostaining and on Western blots with COS-7 cells transiently transfected with an ADAM 12 expression construct (p1095), but not with COS-7 cells transfected with a control vector30 (not shown).

The integrin function-blocking monoclonal antibody AIIB2 developed by C. H. Damsky was obtained from the Developmental Studies Hybridoma Bank maintained by the University of Iowa, Department of Biological Sciences (Iowa City, IA). The integrin α6 function-blocking 2B7 monoclonal antibody26 was a kind gift from Dr. A. M. Mercurio, Harvard Medical School. The IgGs were purified using Protein G-Sepharose as described by the manufacturer (Amersham-Pharmacia, St. Louis, MO). Mouse monoclonal antibodies against β-actin (A-5441, Sigma-Biotech, Horsholm, Denmark) were also used. Fluorescein- and mouse rhodamine-conjugated antibodies against rabbit, rat, and mouse immunoglobulins were purchased from DAKO (Glostrup, Denmark).

Immunohistochemistry on Tissue Sections

For immunostaining on fixed, paraffin-embedded sections, the indirect immunoperoxidase staining technique was used as described.33 Briefly, sections were deparaffinized, and endogenous peroxidase activity was blocked with 10% hydrogen peroxide in methanol for 10 minutes at room temperature. Some sections were subsequently pretreated with pronase (10 μg/ml in buffer for 5 minutes) and rinsed. The primary antisera were applied and incubated with the sections overnight at 4°C in a humidified chamber. Following a thorough rinse, the sections were incubated with peroxidase-coupled swine antirabbit, rabbit anti-mouse, or rabbit anti-rat immunoglobulins. Incubations with both primary and secondary antibodies were performed in 0.05 mol/L Tris-HCl (pH 7.2) and rinses in 0.05 mol/L Tris-HCl (pH 7.2) containing 0.15 mol/L NaCl. The primary antibodies were used in the following dilutions: rb 104 and rb 950 1:200, R20, R21, and R23 1:100. On control sections, the specific antibodies were omitted or replaced with irrelevant mouse or rat monoclonal antibodies of the same isotype or with nonimmune mouse, rat, or rabbit serum. As a further control, the inhibitory effect of simultaneously incubating the antisera with purified recombinant ADAM 12 polypeptide.
was examined. To this end, sections were incubated with serial dilutions of the antisera together with 25 μg/ml of recombinant ADAM 12 or another irrelevant recombinant protein (a protein of same Mr, and purified in the same way). This experiment was repeated three times on different tissue samples with the same results. The slides were mounted in buffered glycerol and examined under a Zeiss LSM-10 laser scan confocal microscope.

Immunostaining on frozen sections were performed essentially as above with the following modifications. Cryostat sections were air-dried and fixed in precooled acetone at 4°C for 15 minutes. Each of the respective antibodies (diluted 1:100) were applied to the sections and incubated for 1 hour. Following a thorough rinse, the sections were incubated with fluorescein isothiocyanate-coupled secondary antibodies 1:50 for 30 minutes.

**Recombinant Proteins**

A series of plasmids for the expression of His-tagged ADAM 12 polypeptides in *E. coli* were constructed. Plasmid p1053, which codes for subdomain b' and c of the cysteine-rich domain of human ADAM 12 and the first four amino acids of carboxy terminus of ADAM 12-S (aa 564–708 of ADAM 12-S) has been described previously. All inserts for the other ADAM 12 plasmids were amplified from an ADAM 12 cDNA template with Pfu DNA polymerase (Stratagene), using the following primers:

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Primers</th>
<th>ADAM 12 Domain</th>
<th>Nucleotides amplified</th>
</tr>
</thead>
<tbody>
<tr>
<td>p1048</td>
<td>5'-dCAGGATCCAGAGAAAGAATCCTAAGGCA-CCCTCAAG 5'-dCAACTGAGCGAGACCATGTCGCTGGTAAACAG</td>
<td>aa 207–416 metalloc- protease</td>
<td></td>
</tr>
<tr>
<td>p1219</td>
<td>5'-dCAGGATCCCTCATGTC-AGGATGTGG 5'-dCAACTGAGGTCGGTGGTCCGGATGG 5'-dGTTTGGCTTTGGAGGAAGCACAG</td>
<td>aa 513–704 cys a+b+c</td>
<td></td>
</tr>
<tr>
<td>p1222</td>
<td>5'-dCAGGATCCGGCAAGGTCTGGAAAGAATCCTAGGCTGCTGG 5'-dCAACTGAGGTCGGATGG 5'-dCAACTGAGGTCGGTGGTCCGGATGG</td>
<td>aa 563–704 cys b’+c</td>
<td></td>
</tr>
<tr>
<td>p1053</td>
<td>BamHI/Xho fragment of ADAM 12-S</td>
<td>aa 564–708 cys b’+c</td>
<td></td>
</tr>
<tr>
<td>p1347</td>
<td>5'-dCAACTGAGGTCGGTGGTCCGGATGG 5'-dCAACTGAGGTCGGTGGTCCGGATGG</td>
<td>aa 417–512 disintegrin</td>
<td></td>
</tr>
</tbody>
</table>

Inserts for the ADAM 15 plasmids were amplified from a human fetal skeletal muscle RT-reaction with Pfu DNA polymerase (Stratagene, La Jolla, CA), using the following primers:

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Primers</th>
<th>ADAM 15 Domain</th>
<th>Nucleotides amplified</th>
</tr>
</thead>
<tbody>
<tr>
<td>p1345</td>
<td>5'-dCAAGAGTCCATGGCTGCTGCTGG 5'-dCAACTGAGGTCGGTGGTCCGG</td>
<td>aa 420–510 disintegrin</td>
<td></td>
</tr>
<tr>
<td>p1346</td>
<td>5'-dCAAGAGTGCGGCGA-CCCGAGTGG 5'-dCAACTGAGGTCGGTGGTCCGGATGG 5'-dCAACTGAGGTCGGTGGTCCGGATGG</td>
<td>aa 561–693 cys b’+c</td>
<td></td>
</tr>
</tbody>
</table>
Specific for Primers Nucleotides amplified
5'-dCAGAAATTTCAAGGAGGCCGGATTCTGGT
Laminin α2 5'-dGAAAGCTACAAAACTGGCAACA-GGT
5'-dTAGGGTATCCACTGTTCCCTGTGAT

After an initial denaturation at 95°C for 60 seconds, 35 cycles of denaturation at 94°C for 15 seconds, annealing at 60°C (for ADAM 12-L) or 55°C (for ADAM 12-S and laminin α2) for 20 seconds, and extension at 72°C for 40 seconds were carried out. The ADAM 12 reaction products were separated on agarose gels, blotted onto Hybond N+ nylon membranes, and hybridized with [32P]dCTP random primed labeled probes specific for ADAM 12-S or ADAM 12-L according to standard procedures. Blots were exposed to Kodak X-Omat AR film for up to 2 hours. To further confirm the identity of the PCR products, the amplified DNA fragments were cloned into the vector pCR 2.1 using the TA cloning kit (Invitrogen, Groningen, The Netherlands), and sequenced with vector primers using the Vistra DNA sequencer 725 (Amerham Pharmacia Biotech).

Cell Attachment Assays

Cells were released from the tissue culture flasks with 10 mmol/L EDTA or with trypsin/EDTA. When trypsin/EDTA was used, cells were incubated at 37°C for 5 minutes in DMEM with 10% fetal bovine serum to allow regeneration of cell surface proteins before rinsing. Both EDTA- and trypsin-released cells were rinsed once in serum-free DMEM and resuspended in the same medium at the concentrations indicated. Cell viability was checked by nigrosin dye exclusion test. The recombinant polypeptides of human ADAM 12 (see above) and for comparison, laminin-1 purified from the Engelbreth-Holm-Swarm (EHS) tumor and human laminin (Gibco-BRL) were used as substrates. An irrelevant recombinant polypeptide of the same M, and purified in the same way and bovine serum albumin (10 mg/ml) served as negative controls. Nunc-Immuno™ 96-well plates with MaxiSorp™ surface (Nunc) were coated with purified recombinant ADAM 12 polypeptides in 0.1 mol/L NaHCO3 buffer overnight at 4°C, rinsed with PBS, and incubated with 10 mg/ml bovine serum albumin in PBS for 1 hour at 37°C. Following a rinse with PBS, 100 μl of cell suspension (0.6 × 105/ml) was added to the wells, which were then incubated at 37°C in 5% CO2 in a humidified atmosphere. After allowing the cells to attach for 1 hour, the wells were rinsed twice in serum-free DMEM, fixed for 20 minutes in 2% glutaraldehyde in 0.1 mol/L cacodylate buffer, pH 7.2, rinsed in PBS, and stained with 0.1% crystal violet in 10% methanol (v/v). Absorbance was measured with an Multiscan enzyme-linked immunosorbent assay reader (Lab-systems, Helsinki, Finland) at 590 nm. A blank value corresponding to an empty well was automatically subtracted. Each assay point was derived from 3 to 6 separate wells and repeated at least two times. To obtain a 100% maximum attachment control, cells were plated in parallel on culture quality 96 well-plates (Costar, Cambridge, MA) in DMEM with 10% fetal bovine serum for 1 hour. To test for adhesion strength the plates were centrifuged in an inverted position at 500 rpm (60 × g) for 2 minutes (PR-6000 centrifuge, Damon/IEC), and the attachment of cells was compared with that of cells in plates that were not subjected to this centrifugal force. To examine the morphology of tumor cells attached, an inverted microscope (Zeiss axiovert) equipped with phase contrast optics was used.

The following experimental conditions were tested: 1) 10 mmol/L EDTA was added to the incubation medium; 2) the incubation temperature was lowered to 4°C; 3) the cells were pretreated for 1 hour with the combination of 50 mmol/L 2-deoxy-D-glucose plus 10 mmol/L sodium azide to inhibit energy production; 39 4) the cells were pretreated with cytochalasin B dissolved in dimethyl sulfoxide to inhibit actin polymerization and as a control with dimethyl sulfoxide at the same final concentration; 5) the cells were preincubated for 15 minutes at room temperature with function-blocking monoclonal antibodies to integrin α6 (2B7) or integrin β1 (AIIb2); 6) the cells were grown in sulfate-free Fischers Medium + 10% dialyzed fetal bovine serum in the presence of 20 mmol/L sodium chloride (Sigma C 3171), an inhibitor of sulfation in living cells,40,41 or as a control with both sodium chloride and 10 mmol/L sodium sulfate, for 24 hours before the assay; 7) the cells or the plates were preincubated with heparin (Sigma H 2149), heparan sulfate (Sigma D-9808), chondroitin A, B, and C (Sigma C 9819, C 0320, C 4384, respectively), and hyaluronic acid (H1751); and 8) the cells were pretreated for 30 minutes with 1 mU/ml heparitinase or 50 mU/ml protease-free chondroitinase ABC (# 100703 and 100332, respectively, Seikagaku Corporation, Japan). Unless otherwise indicated, the various reagents were present throughout the 1-hour attachment assay period.

Indirect Immunofluorescence Microscopy and Time Lapse Microscopy of Attaching Cells

For immunofluorescence staining, cells were rinsed and fixed in cold methanol for 3 minutes, rinsed and incubated with anti-β actin 1:100 for 1 hour at room temperature, and rinsed and incubated with secondary antibodies as described above.

For time-lapse microscopy, cells were plated at low density in a dish, sealed with parafilm, and placed on the microscope stage heated to 37°C. The Axiovert inverted microscope was connected to a PentaMAX-chilled charge-coupled device camera (Princeton Instruments, Inc. Trenton, NJ) and a Dell computer. A frame-by-frame analysis of the cell surface projections at intervals of 2 minutes for 1 hour was used to discriminate between filopodia and retraction fibers. Images were analyzed with the MetaMorph Imaging System (Universal Imaging Corporation, West Chester, PA). For migration studies, the cells were allowed to attach for 30 minutes before placing them on the heated stage. The cell displacement
as a function of time was monitored at 15 minute intervals for 1 hour and analyzed as described.36

**Binding of Human ADAM 12 to Heparin Sepharose**

Full-length ADAM 12-S protein encoded by the plasmid p1151 was produced by transfection of COS-7 cells as previously described.31 One ml of conditioned serum-free UltraDOMA medium was incubated for 3 hours at room temperature with 30 μl of heparin Sepharose Cl-6B beads (Pharmacia). The beads were washed with PBS, and bound protein was then eluted by boiling in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. ADAM 12 protein was detected by SDS-PAGE and Western blotting using the 14E3 mAb as previously described.31 Binding to heparin Sepharose was performed either in the presence of 0.1 mol/L NaCl (as present in UltraDOMA medium) or after the addition of 0.5 mol/L or 1.0 mol/L NaCl.

**Results**

**ADAM 12 Is Present at Tumor Cell Surfaces**

The distribution of ADAM 12 in a series of 37 human carcinomas compared with the normal counterpart tissue was investigated by immunohistochemistry. Representative samples are shown in Figure 1. All 15 cases of breast carcinomas exhibited intense ADAM 12 immunoreactivity (Figure 1A) using several different antibodies, whereas in normal breast tissue, only a few scattered luminal cells of the ducts exhibited ADAM 12 immunoreactivity (Figure 1E). Half of the 14 cases of colon carcinomas, 2 of the 4 cases of gastric, and all 4 cases of lung carcinomas examined exhibited ADAM 12 immunoreactivity (Figure 1, B-D). Little or no immunostaining was observed in the corresponding normal colon epithelium (Figure 1F). In the ADAM 12 positive carcinomas, intense cytoplasmic immunostaining was observed in most of the carcinoma cells. Strikingly, in several areas (Figure 1D) the immunoreactivity was located between tumor cells and at the tumor-stroma interface, an indication that ADAM 12 is found on the tumor cell plasma membrane. The immunostaining was completely abolished when purified recombinant ADAM 12 was added together with the primary antibodies (not shown). In both normal and tumor specimens a strong immunoreactivity for ADAM 12 was present in the smooth muscle of the blood vessel wall. The endothelial cells of the blood vessels and the stromal cells including myofibroblasts did not show any detectable immunoreactivity. The available antibodies did not allow us to discriminate between the presence of ADAM 12-L and ADAM 12-S in the tissue sections. To investigate this question and to confirm the existence of ADAM 12 transcripts in the tissue specimens, we performed RT-PCR.

A series of normal and cancerous human breast tissue specimens were analyzed by RT-PCR using primers that were specific for ADAM 12-L and ADAM 12-S. Breast carcinoma tissue appeared to contain more ADAM 12-L transcript than normal breast tissue (Figure 1G). ADAM 12-S transcript was present in both normal and tumor tissue and appeared to vary among the tissue samples (not shown). Both forms of ADAM 12 could be detected in a range of cultured tumor cell lines (not shown). The identity of the RT-PCR products was confirmed by nucleotide sequencing.

The expression of ADAM 12 in normal tissue, in particular in muscle, has previously been documented.30,31,42 The finding in the present study of an apparent up-regulation of ADAM 12 in human carcinoma, and in particular the intriguing immunostaining pattern, raised the question whether ADAM 12 might play a role in cell-cell and/or cell-matrix interactions in cancer.

**rADAM 12-cys Promotes Tumor Cell Adhesion**

We decided to use an in vitro system to study tumor cell adhesion to human ADAM 12. Our strategy was to express individual domains of human ADAM 12 as recombinant polypeptides in E. coli and assay for their ability to promote tumor cell attachment, similar to the approach that was used for defining the specific interaction between the disintegrin-like domain of human ADAM 15 with integrin αvβ3.43 The metalloprotease, the disintegrin-like, and cysteine-rich domains were individually expressed in E. coli as His-tagged polypeptides. These domains make up the extracellular moiety of ADAM 12 after removal of the prodomain by a furin-type protease.31 and any specific cell-binding activity would be expected to reside in one or more of these domains. As a control, recombinant polypeptides of the disintegrin-like and cysteine-rich domains of human ADAM 15 were generated. A standard cell-attachment assay was used in which tumor cells were allowed to attach for 1 hour in wells coated with the respective substrates. As expected based on the work by Zhang et al,43 we found that αvβ3 integrin-expressing A375 melanoma cells44 attached well to recombinant ADAM 15 disintegrin-like domain, whereas MDA-MB-231 cells that express only low levels of αvβ3 integrin45 did not attach (Figure 2A, 2B). Neither of these two cell lines attached to the recombinant cysteine-rich domain of ADAM 15 (Figure 2B). Interestingly, however, we found that for ADAM 12 the recombinant cysteine-rich domain served as a specific adhesion substrate for the MDA-MB-231 breast carcinoma cells in a concentration-dependent manner, whereas neither the recombinant metalloprotease nor disintegrin-like domains were biologically active in this attachment assay (Figure 2B, 2C). The cysteine-rich domain is composed of three subdomains a, b’, and c.37 To further localize the binding site, we expressed various subdomains of the cysteine-rich domain. Recombinant polypeptides of subdomain b’+c (p1053, p1222) were the most active (Figure 2D). The recombinant b’+c subdomain of the ADAM 12 cysteine-rich domain, hereafter referred to as rADAM 12-cys, was used in further experiments. The attachment to rADAM-cys was dose-dependent, and maximum attachment was obtained at concentrations of 10 to 20 μg/ml. Attachment to
Figure 1. ADAM 12 is up-regulated in carcinoma tissue compared with normal tissue by immunohistochemistry and RT-PCR. Intense ADAM 12 immunostaining is shown in the tumor cells of a breast carcinoma (A), a gastric carcinoma (B), and a colon carcinoma (C and D). The insert in B is a higher magnification of the area indicated by an arrow. A section of normal breast tissue with a few scattered luminal cells of the ducts with ADAM 12 immunoreactivity is demonstrated in E and normal colon epithelium with essentially no ADAM 12 immunoreactivity in F. The sections are counterstained with hematoxylin. Normal human breast and carcinoma tissue was examined by RT-PCR and subsequent Southern hybridization (G) to detect the 516-bp human ADAM 12-L PCR product. Human term placenta served as a positive control. Lanes 1–7 are a series of different breast carcinomas. Lanes 8 and 9 are pairs of normal and tumor tissue from the same patient. NC is a negative control in which template is omitted in the PCR reaction. The bottom panel is a control RT-PCR of the same samples after amplification with primers specific for human laminin α2 chain, yielding a 518-bp product that was detected on a ethidium-bromide stained agarose gel. Scale bars, 35 μm (A and C); 78 μm (B); 16 μm (insert); 17.5 μm (D); 41 μm (E); 44 μm (F).
Figure 2. Cell attachment of human tumor cell lines to recombinant ADAM 12 fragments demonstrates the specificity and dose-dependency of the cysteine-rich domain as a substrate. 

A shows cell attachment of the A375 melanoma cell line to multiwell plates coated with different concentrations of EHS laminin (-○-) and on rADAM 15-disintegrin-like domain (-●-), and the MDA-MB-231 breast carcinoma cell line on EHS laminin (-○-) and on rADAM 15-disintegrin-like domain (-●-). 

B shows cell attachment of the A375 cell line (hatched bars) and the MDA-MB-231 breast carcinoma cell line (black bars) to rADAM 15-cysteine-rich domain, rADAM 15-disintegrin-like domain, rADAM 12-cysteine-rich domain, rADAM 12-disintegrin-like domain, (20 µg/ml). 

C shows cell attachment of the MDA-MB-231 breast carcinoma cell line to multiwell plates coated with different concentrations of human laminin (-○-); rADAM 12-disintegrin-like domain (-●-), rADAM 12-metalloprotease domain (-○-), and rADAM 12-cys (b' + c') (-●-). 

D demonstrates cell attachment of MDA-MB-231 to various subdomains of the cysteine-rich domain: rADAM 12-cys (a + b' + c') p1219 (-○-), rADAM 12-cys (b' + c') p1053 (-●-) and p1222 (-●-). Each point represents the mean ± SEM of triplicate wells. In all experiments the absorbance value of cell attachment to bovine serum albumin was below 0.05 at 590 nm (not shown). Data present the mean ± SEM. 

E demonstrates ADAM 12-cys mediated cell attachment of a series of human tumor cell lines. Cell attachment of several cultured cell lines to wells coated with 20 µg/ml of rADAM 12-cys was compared with wells coated with 20 µg/ml of EHS-laminin. Data present the mean ± SEM. The cell lines are: 1) MDA-MB-231; 2) MDA-MB-435; 3) MDA-MB-468; 4) MCF-7; 5) RKO; 6) Clone A; 7) A431; 8) A375; 9) SK-MEL-28; 10) HT1080; and 11) A204. 

F demonstrates a Coomassie-blue-stained SDS-PAGE with some purified recombinant polypeptides used. Lane 1, the disintegrin-like domain of human ADAM 15 (p1345); lane 2, the cysteine-rich domain of human ADAM 12 (p1053); lane 3, the cysteine-rich domain of human ADAM 12 (p1222). Molecular mass markers (Mark 12, Novex) are indicated.
rADAM12-cys was approximately 60% of maximum attachment obtained on tissue culture plates (not shown). The tumor cells attached firmly to both rADAM-12 cys and laminin substrates as evidenced by their unaltered attachment when the plates were inverted and centrifuged at 60 × g for 2 minutes (not shown). We tested a large series of tumor cells lines (Figure 2E) and found that MDA-MB-231, MDA-MB-435, MDA-MB-468, RKO, Clone A, A431, SK-MEL-28, A375, HT1080, and A204 cells adhered as well to rADAM 12-cys as they did to laminin, whereas MCF-7 cells adhered significantly better to laminin (Figure 2C, column 4).

Adhesion mediated via rADAM 12-cys has distinct physical requirements (Figure 3). The addition of 10 mmol/L EDTA to the incubation medium inhibited the cell attachment, indicating that the cell adhesion to the rADAM 12-cys was dependent on divalent cations (Figure 3A). The rADAM 12-cys mediated adhesion process was temperature independent and, in contrast to the adhesion to laminin, was efficient at 4°C (Figure 3B). The binding of tumor cells to rADAM 12-cys required metabolic energy, because pretreatment and incubation with a mixture of 50 mmol/L 2-deoxy-D-glucose plus 10 mmol/L sodium azide resulted in an almost complete inhibition of attachment (Figure 3C). Cytochalasin B, an inhibitor of actin polymerization, had only a minor effect on attachment but inhibited the formation of cell surface projections (not shown).

Tumor Cells Attach to rADAM 12-cys with a Rounded Morphology Accompanied by Numerous Actin-Containing Filopodia

Morphological analysis of tumor cell adhesion to rADAM 12-cys after 1 hour revealed a distinct pattern of cell shape. The tumor cell lines, such as MDA-MB-231 breast carcinoma cells, remained rounded and had a number of cell surface projections radiating from the central soma without any apparent polarization (Figure 4A). In contrast nearly all cells plated on laminin were spread (Figure 4B). The numerous cell surface projections contained actin as evidenced by immunostaining with monoclonal antibodies to β-actin (Figure 4C, 4D). A critical role for actin was also indicated by the observation that these projections did not form on adhering cells in the presence of cytochalasin B (not shown). To examine whether the actin-containing projections were caused by membrane protrusions (filopodia) or by membrane retractions (retraction fibers), we used time-lapse microscopic analysis.2,36 We found that the thin cell surface projections actively protruded from the cells (not shown) and began to appear a few minutes after plating the cells. In some cells, lamellae developed around the cells secondary to the formation of cell surface projections. These cell surface projections were therefore considered to be filopodia.

A combination of a rounded morphology, filopodia, and lamella formation is characteristic of migrating cells and led us to test the ability of rADAM 12 to stimulate tumor cell migration. Because Clone A cells have been demonstrated to migrate spontaneously and can be further stimulated by laminin,36 we compared the migration rate of these cells on rADAM 12-cys substrate with migration on uncoated tissue culture plastic or on EHS-laminin. Clone A cells exhibited a random migration at a rate of 19.9 ± 5.4 μm/h on plastic, 36.7 ± 5.1 μm/h on EHS-laminin, and 9.0 ± 1.1 μm/h on rADAM 12. We conclude that rADAM 12-cys does not appear to stimu-
late cell migration but appears to retard spontaneous migration \((P < 0.0001;\) Student’s t-test).

**rADAM 12-cys Mediates Tumor Cell Adhesion Through Cell a Surface Heparan Sulfate Proteoglycan**

The results obtained so far indicated that rADAM 12-cys represents a tumor cell attachment stimulus, but what are the receptor(s) and the molecular mechanisms involved? The integrin family of cell surface proteins are primary participants in cell adhesion to extracellular matrix molecules and to other cells. We found that function-blocking monoclonal antibodies to integrin \(\alpha 6(2B7)\) and \(\beta 1(\text{AlIB2})\) did not inhibit significantly attachment to rADAM 12-cys (Figure 5A and not shown) of the MDA-MB-231 cells. As expected, attachment to laminin was perturbed by both antibodies (Figure 5A). Another candidate cell receptor family is the sulfated cell membrane proteoglycans. Sulfation of glycosaminoglycans was inhibited by growing cells in culture media containing sodium chlorate. At a concentration of 20 mmol/L chlorate, more than 95% decrease in cell attachment to rADAM 12-cys was seen (Figure 5B). The effect of chlorate on cell attachment could be almost completely reversed by inclusion of 10 mmol/L sodium sulfate in the cell cultures (Figure 5B). No effect of sodium chlorate was observed in MDA-MB-231 cell attachment to laminin. These results suggest that sulfated glycosaminoglycans are of critical importance for cell attachment to rADAM 12-cys.

To determine which class of sulfated cell membrane proteins are involved, we examined the effect on cell attachment to rADAM 12-cys and laminin of a series of inhibitors of glycosaminoglycan function, including heparin, heparan sulfate, chondroitin sulfate A, B, and C, and as a control nonsulfated hyaluronic acid. Cell attachment to rADAM 12-cys was completely inhibited by heparin and heparan (Figure 5C, 5D). Notably, cell attachment was inhibited when heparin was preincubated for 30 minutes with the rADAM12-cys coated wells and the wells rinsed before addition of the cells. Thus, heparin was not binding to the tumor cell surfaces but rather was binding to the rADAM 12-cys substrate and thereby blocking cell adhesion to rADAM 12-cys by competitive inhibition. We found no dose-dependent effect of chondroitin sulfate A, B, and C or hyaluronic acid (Figure 5C and not shown). Furthermore, enzymatic removal of glycosaminoglycans by treatment of the cells with 1 mU/ml heparatinase significantly reduced the cell attachment, whereas 50 mU/ml chondroitinase ABC had no effect (Figure 5C). No significant effect of any of these compounds was observed in MDA-MB-231 cell attachment to laminin (Figure 5D and

![Figure 4](image-url). Morphology of tumor cells attaching to rADAM 12-cys. MDA-MB-231 breast carcinoma cells were seeded on rADAM 12-cys (A) or EHS-laminin (B) for 1 hour, fixed, stained with crystal violet, and photographed using phase contrast optics, as described in Materials and Methods. The MDA-MB-231 cells attained a rounded morphology with many cell surface projections on the rADAM 12-cys substrate (A) compared with a flattened and spread morphology on EHS-laminin (B). MDA-MB-231 (C) and RKO carcinoma cells (D and E) were seeded on rADAM 12-cys for 1 hour, were fixed, and reacted with antibodies to \(\beta\)-actin. Numerous cell surface projections irradiating from the cells stained positively (C and D). Note in (D) that the projections of adjacent cells appeared to contact each other. E is a control staining where the primary antibody was omitted. Scale bar, 14.5 \(\mu\text{m}(\text{A and B}); 7.5 \mu\text{m}(\text{C-E}).\)
These results suggest that for MDA-MB-231 cells, heparan sulfate chains are critically involved in rADAM 12-cys-mediated cell attachment. Several other cell lines (RKO, Clone A, and A375 cells) were tested, and the same inhibitory effect of heparin was observed. The data shown above indicate that ADAM 12 interacts with tumor cell surface heparan-sulfate proteoglycans. It should be stressed that the data were obtained using recombinant fragments of ADAM 12 expressed in E. coli, which may be not folded in the same configuration as in full-length native ADAM 12. As a way of testing whether authentic and full-length human ADAM 12 can interact with heparan-sulfate proteoglycan(s), we tested the ability of such protein to bind to heparin Sepharose. ADAM 12-S protein was produced by transfecting COS cells with an expression plasmid for full-length human ADAM 12-S.31 Conditioned medium containing the 92-kd proform and the 68-kd active protease was incubated with heparin-Sepharose in the presence of increasing amounts of NaCl. Bound material was eluted and analyzed by SDS-PAGE. Figure 5 shows that both forms of ADAM 12-S bind to heparin-Sepharose and that this binding is eliminated at increased ionic strength as is seen for known heparan-sulfate binding proteins. Both the 68- and 92-kd forms of ADAM 12 contain the cysteine-rich domain; therefore this result is consistent with the observation that ADAM 12 binds heparin-Sepharose.

Figure 5. MDA-MB-231 cell attachment to rADAM 12-cys is mediated through a cell surface heparan sulfate proteoglycan. A shows the effect of function-blocking β1 integrin antibodies on attachment to rADAM 12-cys and to EHS-laminin of MDA-MB-231 cells. MDA-MB-231 cells on rADAM 12-cys (●) and on EHS-laminin (○). Note that the antibodies completely inhibited attachment to laminin as expected, but that no dose response was obtained on attaching to rADAM 12-cys. B shows that MDA-MB-231 cells grown in the presence of 20 mmol/L sodium chloride (hatched bars) are inhibited in their cell attachment on rADAM 12-cys compared with cultures without the addition of sodium chloride (open bars) or with the addition of 10 mmol/L sodium sulfate (cross-hatched bars). No effect of sodium chloride (hatched bars) on cell attachment to laminin compared with untreated cells (open bars) was observed. Data present the mean ± SEM. C demonstrates the effect of 10 μg/ml each of heparin, heparan, chondroitin sulfate A, B, C, and hyaluronic acid as well as 1 mU/ml heparitinase or 50 mU/ml chondroitinase ABC. Note that MDA-MB-231 cell attachment is sensitive to heparin, heparan, and heparitinase. D demonstrates a dose response of heparin on cell attachment to rADAM 12-cys (●) and to laminin (○). Note that low doses of heparin inhibited the attachment of MDA-MB-231 cells. No effect of heparin was observed on cell attachment to laminin. Data present the mean ± SEM.
the results obtained in this study using individual domains expressed in *E. coli*.

**Discussion**

The concept that ADAM proteins serve as cell adhesion proteins through binding to an integrin has emerged from a series of studies of the role of fertilins and cyritestin in fertilization.6-23 Moreover, a recombinant disintegrin-like domain of human MDC 15 (metargidin, ADAM 15) expressed in *E. coli* was shown to function as an RGD-dependent adhesion molecule.34 In agreement with the work of Zang et al,43 we showed that the recombinant disintegrin-like domain of human ADAM 15 supported cell adhesion of cells that express αvβ3 integrin but not of cells lacking this integrin. The recombinant disintegrin-like domain of human ADAM 12 did not support cell adhesion in our assay. This may be due to the fact that ADAM 12 does not contain an RGD tripeptide as does ADAM 15, although we cannot exclude the possibility that it results from a difference in the ability of the *E. coli*-produced polypeptides to fold properly. Because most ADAMs in fact do not have an RGD peptide in the disintegrin-like domain, it will be interesting to explore whether the cysteine-rich domain of other ADAMs may also be assigned a role in cell adhesion.

We explored the molecular mechanism of rADAM 12-cys mediated cell attachment, aiming first at defining the receptor complex(es) involved. Cell attachment to rADAM 12-cys required metabolic energy and involved reorganization of the actin microfilaments. These observations suggest that ADAM 12-cys mediated cell attachment results in intracellular signaling events. For MDA-MB-231 cells that attached but did not spread, we found that the cells attached to rADAM 12-cys by engaging cell surface heparan sulfate chains but apparently not chondroitin sulfate chains. This conclusion is based on attachment assays in which heparin, heparan, and pretreatment of the cells with heparitinase almost completely inhibited attachment. The cysteine-rich domain of human ADAM 12 has no distinct heparin-binding site based on the amino acid sequence, although it is rich in basic amino acids. Candidate cell surface receptors containing heparan sulfate chains include the syndecan family of cell surface proteoglycans, the phosphatidylinositol-linked glypicans, and part-time proteoglycans betaglycan and CD44E.47-50 Several studies have demonstrated a role of syndecans in regulating cell adhesion and morphology.51-57 There are four members of the syndecan family (for review see Refs. 47-50). Their heparan sulfate chains bind to a large number of molecules, including extracellular matrix components such as fibronectin, collagen, thrombospondin, and heparin-binding growth factors such as the FGF's. Syndecans have a distinct, sometimes overlapping tissue distribution pattern.58 There is evidence that syndecan-1 is required for maintenance of normal epithelial cells,59,60 that it can suppress tumor growth,61 and that the expression is down-regulated in cancer.62-64 Little is known about the expression pattern and function of syndecan-4 in cancer; however, in keeping with previous results,64 we found that syndecan-4 transcripts are readily detectable in several of the tumor cell lines, including MDA-MB-231, Clone A, and A375 cells (Gilpin and Wewer, unpublished observations). Interestingly, syndecan-4 localizes to focal adhesions and regulates the distribution and activity of protein kinase C, thus providing direct transmembrane signaling.54,65,66 Although it is tempting to speculate, more rigorous bio-
chemical studies are notoriously needed to define if and by which mechanism syndecan-4 or another of the heparan sulfate bearing cell membrane proteins transduce the rADAM 12-cys-mediated cell adhesion response.

We have found that ADAM 12 expression is up-regulated in human carcinoma tissue, that it appears to be located at the tumor cell surfaces, and furthermore that the cysteine-rich domain of ADAM 12 supports cell adhesion in an in vitro assay. This new class of interactions between an ADAM protein and tumor cell surfaces appears to involve heparan sulfate proteoglycan(s) as receptors or as co-receptors in cell-cell interactions. Alternatively, the secreted form of ADAM 12, ADAM 12-S, may be incorporated in the extracellular matrix and serve as a ligand for the same cell surface receptors. Our results indicate that human ADAM 12 mediates cell-cell or cell-matrix adhesion, but we do not yet know whether ADAM 12-S itself functions as a receptor and initiates a distinct downstream signaling on its own, nor how this may influence tumor cell behavior. In any event, our results may initiate a new avenue of studies aiming at defining the role of the cysteine-rich domain of other ADAM proteins in cell adhesion.

Acknowledgments

We thank Dr. Arthur M. Mercurio for stimulating discussions and help with the manuscript, Dr. Eva Engvall for helpful comments on the manuscript, Brit Valentin, Aase Valsted, and Hiroko Iba for technical assistance, and Bent Børgesen for photography.

References
